Sermorelin

Sermorelin is a synthetic peptide comprising the first 29 amino acids of endogenous GHRH (GHRH 1-29 NH₂), studied in non-human research models in relation to GHRH receptor (GHRHR) binding, anterior pituitary signaling, and somatotropic axis pathway activity. Scientific literature examines this compound in the context of hypothalamic-pituitary axis regulation, pulsatile growth hormone secretagogue signaling behavior, and GHRH receptor pharmacology in controlled non-human research environments.

Research applications commonly explored in the literature include:

GHRH receptor (GHRHR) binding activity and anterior pituitary signaling pathway investigation in non-human models

Somatotropic axis regulation and hypothalamic-pituitary peptide signaling research

Pulsatile growth hormone secretagogue pathway modeling in non-human neuroendocrine research frameworks

Comparative GHRH analogue activity and receptor binding selectivity studies across truncated peptide sequences

GHRH fragment pharmacology and structure-activity relationship research in controlled laboratory settings

The lyophilized vial format allows researchers to evaluate compound stability, reconstitution characteristics, and handling parameters within controlled laboratory settings, supporting consistency across experimental preparation. Each Sermorelin 5mg vial from KÖLD is prepared and filled in the United States under sterile laboratory conditions. All batches are verified by independent third-party laboratories for purity, volume accuracy, and molecular identity.

1. What is Sermorelin studied for in research settings?
Sermorelin appears in scientific literature in relation to GHRH receptor binding, anterior pituitary signaling, and somatotropic axis pathway activity. Research models investigate its behavior as a truncated GHRH analogue within hypothalamic-pituitary axis and growth hormone secretagogue signaling frameworks in non-human systems.

2. What is the structural classification of Sermorelin and how does it relate to GHRH?
Sermorelin is a synthetic 29-amino acid peptide representing the biologically active N-terminal fragment of endogenous GHRH (residues 1–29). Scientific literature examines how this truncated sequence retains GHRHR binding activity relative to the full 44-amino acid endogenous sequence, making it a useful tool compound in GHRH receptor pharmacology and structure-activity relationship research.

3. How does Sermorelin differ from CJC-1295 without DAC in research contexts?
Both compounds are studied as GHRH receptor agonists in non-human models, but their structural profiles differ. Sermorelin represents the native GHRH 1–29 fragment with no structural modifications, while CJC-1295 without DAC incorporates amino acid substitutions studied for their effect on receptor binding affinity and metabolic stability. Scientific literature examines these structural differences in the context of comparative GHRH analogue pharmacology research.

4. Is Sermorelin approved for any use in humans or animals?
No. Sermorelin is not approved for human or veterinary use in the context in which KÖLD sells it. All products sold by KÖLD are strictly for in vitro and non-human laboratory research purposes only.

5. How is purity and quality verified?
Each Sermorelin 5mg vial undergoes independent third-party laboratory testing to confirm molecular identity, purity, and volume accuracy prior to release.

Before Reconstitution

Store sealed vial in a freezer at -20°C (–4°F)

Keep away from light and humidity

After Reconstitution

Store at 4°C (39°F)

Use within 14 days

Avoid repeated freeze-thaw cycles

This compound is supplied as a lyophilized powder.
Use KÖLD Solution (sterile, lab-grade solvent) if your protocol requires reconstitution.
Reconstitute only when ready to begin your study.
For research use only. Not for human or animal use.
Not intended to diagnose, treat, cure, or prevent any disease.